Nektar Therapeutics 8-K Filing

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke

Filing Documents

• ea0266707-8k_nektar.htm (8-K) — 26KB
• 0001213900-25-113606.txt ( ) — 185KB
• nktr-20251121.xsd (EX-101.SCH) — 3KB
• nktr-20251121_lab.xml (EX-101.LAB) — 33KB
• nktr-20251121_pre.xml (EX-101.PRE) — 22KB
• ea0266707-8k_nektar_htm.xml (XML) — 3KB

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On November 21, 2025, Nektar Therapeutics ("Nektar") announced that Mark A. Wilson will step down as Chief Legal Officer of Nektar, effective as of December 31, 2025. Mr. Wilson's departure is not the result of any disagreement with Nektar on any matter relating to its operations, policies or practices. Elizabeth Zhang, Nektar's Vice President, Legal and Corporate Counsel, will be taking over Mr. Wilson's responsibilities. Ms. Zhang has been with Nektar since 2021 after prior positions at Cravath, Swaine & Moore LLP in New York City and Gibson, Dunn & Crutcher LLP in San Francisco. Ms. Zhang holds a Bachelor of Arts in Neurobiology from Harvard College, a Master of Science in Neuroscience from the University of Oxford, and a Juris Doctor from Harvard Law School.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: November 21, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2

View Full Filing

View this 8-K filing on SEC EDGAR